Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECRAID-Prime primary care adaptive platform trial for COVID-19 and COVID-like illness
2022-501707-27-01Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2024
- Modality
- Modified Peptides → Peptides, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of nitric oxide, voxvoganan and saline in coronavirus disease 2019 (COVID-19) and Acute Respiratory Viral Infections (4 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Time to first self-report of feeling recovered from symptoms related to COVID-19 or COVID-like illness, Viral clearance and potential reduction in viral load and or impact on biomarkers of illness severity from baseline to intervention-specific days between day 1 and day 14 and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
nitric oxidevoxvoganansaline
03
Conditions
coronavirus disease 2019 (COVID-19)Acute Respiratory Viral Infections
Beyond the preview
Go deeper on 2022-501707-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501707-27-01.